H Chen1, H Tu, Z Q Meng, Z Chen, P Wang, L M Liu. 1. Department of Hepatobiliary & Pancreatic Oncology, Cancer Hospital, Fudan University, Shanghai, China.
Abstract
OBJECTIVE: To determine the prognostic value of K-ras mutations in plasma DNA of unresectable pancreatic cancer patients. METHODS: Blood samples were collected from 91 patients with unresectable pancreatic cancer prior to treatment. K-ras gene was amplified from the circulating plasma DNA. Mutations were detected by direct sequencing. The relationship between the types of K-ras gene and prognosis of unresectable pancreatic cancer was evaluated. RESULTS: K-Ras codon 12 mutations were found in 30 of 91(33%) plasma DNA samples, 17mutations were c.35G>A (p.G12D), 11 were c.35G>T (p.G12V) and only 2 were c.34G>C (p.G12R)). K-ras codon 12 mutations could significantly reflect the clinical parameters, including TNM tumor staging (P=0.033) and liver metastasis (P=0.014). The median survival time of patients with K-ras mutations was shorter than that of patients with wild-type K-ras gene (3.9 months vs. 10.2 months, P<0.001). K-ras codon 12 mutation from plasma DNA was an independent negative prognostic factor for survival (hazard ratio, 7.39; 95% confidence interval, 3.69-14.89). CONCLUSION: K-ras mutation in plasma DNA is a predictive biomarker for a poor prognosis of unresectable pancreatic cancer patients.
OBJECTIVE: To determine the prognostic value of K-ras mutations in plasma DNA of unresectable pancreatic cancerpatients. METHODS: Blood samples were collected from 91 patients with unresectable pancreatic cancer prior to treatment. K-ras gene was amplified from the circulating plasma DNA. Mutations were detected by direct sequencing. The relationship between the types of K-ras gene and prognosis of unresectable pancreatic cancer was evaluated. RESULTS:K-Ras codon 12 mutations were found in 30 of 91(33%) plasma DNA samples, 17mutations were c.35G>A (p.G12D), 11 were c.35G>T (p.G12V) and only 2 were c.34G>C (p.G12R)). K-ras codon 12 mutations could significantly reflect the clinical parameters, including TNM tumor staging (P=0.033) and liver metastasis (P=0.014). The median survival time of patients with K-ras mutations was shorter than that of patients with wild-type K-ras gene (3.9 months vs. 10.2 months, P<0.001). K-ras codon 12 mutation from plasma DNA was an independent negative prognostic factor for survival (hazard ratio, 7.39; 95% confidence interval, 3.69-14.89). CONCLUSION:K-ras mutation in plasma DNA is a predictive biomarker for a poor prognosis of unresectable pancreatic cancerpatients.
Authors: Stefan Boeck; Andreas Jung; Rüdiger P Laubender; Jens Neumann; Rosalind Egg; Clara Goritschan; Steffen Ormanns; Michael Haas; Dominik P Modest; Thomas Kirchner; Volker Heinemann Journal: J Gastroenterol Date: 2013-02-23 Impact factor: 7.527
Authors: K Allenson; J Castillo; F A San Lucas; G Scelo; D U Kim; V Bernard; G Davis; T Kumar; M Katz; M J Overman; L Foretova; E Fabianova; I Holcatova; V Janout; F Meric-Bernstam; P Gascoyne; I Wistuba; G Varadhachary; P Brennan; S Hanash; D Li; A Maitra; H Alvarez Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: Thomas Semrad; Afsaneh Barzi; Heinz-Josef Lenz; Irene M Hutchins; Edward J Kim; I-Yeh Gong; Michael Tanaka; Laurel Beckett; William Holland; Rebekah A Burich; Leslie Snyder-Solis; Philip Mack; Primo N Lara Journal: Int J Clin Oncol Date: 2014-08-05 Impact factor: 3.402